DrugPatentWatch Database Preview
Flibanserin - Generic Drug Details
What are the generic drug sources for flibanserin and what is the scope of freedom to operate?
Flibanserin
is the generic ingredient in one branded drug marketed by Sprout Pharms and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Flibanserin has eighty-one patent family members in thirty-one countries.
One supplier is listed for this compound.
Summary for flibanserin
| International Patents: | 81 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 50 |
| Clinical Trials: | 17 |
| Patent Applications: | 436 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | flibanserin at DailyMed |
Recent Clinical Trials for flibanserin
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mohit Khera | Phase 2 |
| Sprout Pharmaceuticals, Inc | Phase 2 |
| University of Chicago | N/A |
Pharmacology for flibanserin
| Mechanism of Action | P-Glycoprotein Inhibitors |
Synonyms for flibanserin
| 1-(2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)-1H-benzo[d]imidazol-2(3H)-one |
| 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one |
| 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-(piperazinyl)ethyl)-2-benzimidazolinone |
| 1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2H-benzimidazol-2-one |
| 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one |
| 167933-07-5 |
| 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]- |
| 2H-Benzimidazol-2-one,1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]- |
| 3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-1H-benzimidazol-2-one |
| 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one |
| 37JK4STR6Z |
| 933F075 |
| A810922 |
| AC1OCF7H |
| Addyi |
| Addyi (TN) |
| AKOS005146139 |
| AM84577 |
| API0006409 |
| AT-16920 |
| BCP02131 |
| Bimt 17 |
| BIMT 17 BS |
| Bimt-17 |
| BIMT-17-BS |
| CHEBI:90865 |
| CHEMBL231068 |
| CS-4671 |
| D02577 |
| DB04908 |
| Female Viagra (Street Name) |
| Female Viagra [Street Name] |
| Flibanserin (USAN/INN) |
| Flibanserin [USAN:INN] |
| FT-0659246 |
| Girosa |
| Girosa (proposed trade name) |
| GTPL8182 |
| HSDB 8278 |
| HY-A0095 |
| KS-00000293 |
| L001463 |
| MolPort-006-170-023 |
| NCGC00386567-01 |
| SC-28449 |
| SCHEMBL247579 |
| UNII-37JK4STR6Z |
| ZINC52716421 |
US Patents and Regulatory Information for flibanserin
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sprout Pharms | ADDYI | flibanserin | TABLET;ORAL | 022526-001 | Aug 18, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Sprout Pharms | ADDYI | flibanserin | TABLET;ORAL | 022526-001 | Aug 18, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Sprout Pharms | ADDYI | flibanserin | TABLET;ORAL | 022526-001 | Aug 18, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for flibanserin
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Montenegro | P42808 | Start Trial |
| Spain | 2266632 | Start Trial |
| Serbia | 50742 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
Major Patent Expirations 2019 - 2020
NCE-1 Generic Application Dates 2019 - 2020
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.